Canaccord Genuity Maintains Buy on Regulus Therapeutics, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Regulus Therapeutics (NASDAQ:RGLS) and raises the price target from $11 to $28.
June 25, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Regulus Therapeutics and significantly raises the price target from $11 to $28.
The significant increase in the price target from $11 to $28 by a reputable analyst is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100